Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms

NCT01908829 is registered in ClinicalTrials.gov with Astellas Pharma Europe Ltd. as lead sponsor.

NCT NCT01908829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01908829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms
Lead sponsor
Astellas Pharma Europe Ltd.
Phase
Phase 3
Overall status
Completed
Start date
July 10, 2013
Completion date
November 25, 2014
Enrollment
2,174 (actual)
Sites
219

Conditions

As the registry lists them; a condition with its own page is linked.

urinary bladder diseases, urinary bladder overactive, urologic diseases